The effect of onabotulinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis
- 483 Downloads
This study assessed the efficacy and safety of onabotulinumtoxinA according to injection site for treatment of overactive bladder.
A systematic literature review located randomized controlled trials of onabotulinumtoxinA treatment for neurogenic detrusor overactive bladder and idiopathic overactive bladder in adults. We searched MEDLINE, EMBASE, and the Cochrane Controlled Trials Register using the Ovid platform. Meta-analysis was based on Cochrane Review Methods.
Eight studies (419 participants) were included. Trigone-including injection demonstrated a significant improvement in symptom score (SMD = − 0.53, 95% CI − 1.04 to − 0.02, P = 0.04, I 2 = 78%), higher complete dryness rates (OR = 2.19 patients, 95% CI 1.32–3.63, P = 0.002, I 2 = 41%), and lower frequency of incontinence episodes (WMD = − 0.85 per day, 95% CI − 1.55 to − 0.16, P = 0.02, I 2 = 87%) in patients. Comparing trigone-including injection to trigone-sparing injection, lower detrusor pressure (WMD = − 2.55 cm H2O, 95% CI − 4.16 to − 0.95, P = 0.002, I 2 = 0%) and higher volume at first desire to void (WMD = 17.54 ml, 95% CI 1.00–34.07, P = 0.04, I 2 = 0%) were observed with trigone-including injection. Between intradetrusor and suburothelial injection sites, there were no differences in efficacy or safety regarding the incidence of vesicoureteral reflux, hematuria, general weakness, bladder discomfort, large post-void residual, and urinary tract infection.
Trigone-including onabotulinumtoxinA injection has superior efficacy to trigone-sparing injection without increased complications. The depth of injection does not influence the efficacy or safety of onabotulinumtoxinA.
KeywordsNeurogenic detrusor overactive bladder Idiopathic overactive bladder Meta-analysis OnabotulinumtoxinA
Hospital funding only by the research fund of Hanyang University (HY-2017).
JKJ: study design, data acquisition, analysis and interpretation of data, and writing of the article; KNK: study design, data acquisition, analysis and interpretation of data, and writing of the article; DWK: data acquisition and interpretation of data; YTK: data acquisition; JYK: organizing data; JYK: organizing data and preparing manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- 1.Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21(2):167–178CrossRefPubMedGoogle Scholar
- 3.Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50(6):1306–1314. https://doi.org/10.1016/j.eururo.2006.09.019 (discussion 1314–1305) CrossRefPubMedGoogle Scholar
- 10.Sexton CC, Notte SM, Maroulis C, Dmochowski RR, Cardozo L, Subramanian D, Coyne KS (2011) Persistence and adherence in the treatment of overactive bladder syndrome with anticholinergic therapy: a systematic review of the literature. Int J Clin Pract 65(5):567–585. https://doi.org/10.1111/j.1742-1241.2010.02626.x CrossRefPubMedGoogle Scholar
- 14.Higgins JP, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration. http://handbook.cochrane.org. Accessed Apr 2017
- 16.Hui C, Keji X, Chonghe J, Ping T, Rubiao O, Jianweng Z, Xiangrong D, Liling Z, Maping H, Qingqing L, Qiuling L, Jiebing H, Tanghai H (2016) Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity. Spinal Cord 54(1):46–50. https://doi.org/10.1038/sc.2015.143 CrossRefPubMedGoogle Scholar
- 17.Huang M, Chen H, Jiang C, Xie K, Tang P, Ou R, Zeng J, Liu Q, Li Q, Huang J, Huang T, Zeng W (2016) Effects of botulinum toxin A injections in spinal cord injury patients with detrusor overactivity and detrusor sphincter dyssynergia. J Rehabil Med 48(8):683–687. https://doi.org/10.2340/16501977-2132 CrossRefPubMedGoogle Scholar
- 19.Manecksha RP, Cullen IM, Ahmad S, McNeill G, Flynn R, McDermott TE, Grainger R, Thornhill JA (2012) Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 61(5):928–935. https://doi.org/10.1016/j.eururo.2011.10.043 CrossRefPubMedGoogle Scholar
- 23.Samal V, Mecl J, Sram J (2013) Submucosal administration of onabotulinumtoxinA in the treatment of neurogenic detrusor overactivity: pilot single-centre experience and comparison with standard injection into the detrusor. Urol Int 91(4):423–428. https://doi.org/10.1159/000350247 CrossRefPubMedGoogle Scholar
- 28.Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C (2010) Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 184(6):2416–2422. https://doi.org/10.1016/j.juro.2010.08.021 CrossRefPubMedGoogle Scholar
- 29.Mehnert U, Boy S, Schmid M, Reitz A, von Hessling A, Hodler J, Schurch B (2009) A morphological evaluation of botulinum neurotoxin A injections into the detrusor muscle using magnetic resonance imaging. World J Urol 27(3):397–403. https://doi.org/10.1007/s00345-008-0362-0 CrossRefPubMedGoogle Scholar